559. Efficacy and Tolerability of Integrase Inhibitors – Experiences from a Nationwide Real-life Cohort
Session: Poster Abstract Session: HIV: Antiretroviral Therapy
Thursday, October 4, 2018
Room: S Poster Hall
Background: The integrase strand transfer inhibitors (INSTIs) are widely used in first-line and alternative antiretroviral therapy. Observational studies have documented a 2–12% incidence of adverse drug reactions sometimes leading to INSTI discontinuation.

Methods: Prospectively collected cohort data of INSTI use were analysed between January 2008 and March 2017, in Hungary, a Central-European country with centralized HIV care. Efficacy of viral supression and reasons for discontinuation were evaluated for available INSTIs (raltegravir (RAL) and dolutegravir (DTG)).

Results: There were 2232 patients registered in the national HIV Center in 2017 March 31. Sixhundred seventeen patients received during the study period RAL (259 patients – 41.9%) or DTG (358 – 58.1%). There were 55 cases (9%) of switch within class (39 patient for simplification, 13 due to toxicity, 2 virological failures, 1 other reason). Sixteen cases (3%) changed INSTI to another class (8 virological failures, 4 due to toxicity, 4 other reason). Ten cases of virological failure occured in patients taking RAL, whereas none of those taking DTG, but in patients on DTG higher rates of side efects were observed compared to patients on RAL (11 – 3.1% vs 6 – 2.3%, respectively).

Conclusion: Large and homogenous, nationwide cohort of patients taking INSTIs confirm good tolerability and excellent efficacy of the class with slight differences between RAL and DTG.

Botond Lakatos, MD PhD1, Bernadett Lonkai, Student2 and János Szlávik, MD1, (1)Infectious Diseases, National Institute of Hematology and Infectious Diseases, Budapest, Hungary, Budapest, Hungary, (2)Semmelweis University, Faculty of MEdicine, Budapest, Hungary


B. Lakatos, None

B. Lonkai, None

J. Szlávik, None

Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 3rd with the exception of research findings presented at the IDWeek press conferences.